Dr. Hudis Discusses Axillary Lymph Node Status

Clifford A. Hudis, MD
Published Online: Tuesday, January 10, 2012
Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the utility of detailed information on the axillary lymph node status for the management of early-stage breast cancer.

Historically, physicians have been taught that the prognosis will worsen as the number of nodes involved increases, which denotes a higher risk for recurrence and warrants the use of chemotherapy. The idea behind this method is a relative risk reduction when giving chemotherapy; the higher the risk the greater the measureable benefit.

Chemotherapy is not always effective and is unique in regards to risks and benefits. Hudis provides tamoxifen as an example; in estrogen receptor (ER)-positive breast cancer tamoxifen is very successful and demonstrates a large benefit, however ER-negative patients do not receive any benefits. The effects are independent of anatomy and are derived from biology and the presence of a biomarker.

A tumors susceptibility to chemotherapy is also based on certain biological subtypes. Some cancers are more sensitive than others. Chemotherapy sensitivity is driven by biological states, not anatomy. Hudis notes that this conclusion results in it no longer being necessary to have extremely accurate historical lymph node status information to make a treatment decision.
Online CME Activities
Free CME from PER
Advances in ImmunoOncology: Intralesional Oncolytic Immunotherapy in Melanoma
Updates in the Treatment of Lung Cancer
10th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® Medical Crossfire®
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
More Reading
$auto_registration$